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ABSTRACT The N-end rule relates the in vivo half-life of
a protein to the identity of its amino-terminal residue. Distinct
versions of the N-end rule operate in all organisms examined,
from mammals to bacteria. We show that UBC2(RAD6), one
of at least seven ubiquitin-conjugating enzymes in the yeast
Saccharomyces cerevisiae, is essential for multiubiquitination
and degradation of the N-end rule substrates. We also show
that UBC2 is physically associated with UBR1, the recognition
component of the N-end rule pathway. These results indicate
that some of the UBC2 functions, which include DNA repair,
induced mutagenesis, sporulation, and regulation of retro-
transposition, are mediated by protein degradation via the
N-end rule pathway.
Selective protein degradation underlies the elimination of
damaged or otherwise abnormal proteins and the temporal
control of many cellular processes that involve short-lived
regulators. At least some proteins are short-lived in vivo
because they contain sequences (degradation signals) that
make these proteins substrates of specific proteolytic path-
ways. An essential component of one degradation signal is
the protein's amino-terminal residue (1). The presence of this
signal, named the N-degron (2), is manifested as the N-end
rule, which relates the metabolic stability of a protein to the
identity of its amino-terminal residue (1). Distinct versions of
the N-end rule operate in all organisms examined, from
mammals to bacteria (refs. 1-12; J. Tobias, T. Shrader, G.
Rocap, and A.V., unpublished data). The eukaryotic N-de-
gron is a bipartite signal, comprising a destabilizing amino-
terminal residue (1) and a specific internal Lys residue (6, 8,
9).
The N-end rule is organized hierarchically (Fig. 1). Spe-
cifically, amino-terminal Asp and Glu (and Cys in mammalian
reticulocytes) are secondary destabilizing residues in that
they are destabilizing through their ability to be conjugated to
Arg, one of the primary destabilizing residues (1, 7, 10, 12).
Amino-terminal Asn and Gln are tertiary destabilizing resi-
dues in that they are destabilizing through their ability to be
converted, via selective deamidation, into the secondary
destabilizing residues Asp and Glu (Fig. 1) (7).
In the yeast Saccharomyces cerevisiae, the recognition
component of the N-end rule pathway is encoded by the
UBRI gene (11). The 225-kDa UBR1 protein, named N-re-
cognin [also known as the type 1, 2 E3 protein (5, 7, 13)],
selects potential proteolytic substrates by binding to their
primary destabilizing amino-terminal residues (Fig. 1) (6, 11).
The yeast N-recognin (11, 14) and its mammalian counter-
parts (5, 7, 13, 16, 18) each possess distinct binding sites for
the two classes of primary destabilizing residues. The type 1
binding site is specific for the positively charged amino-
terminal residues Arg, Lys, and His. The type 2 binding site
is specific for the bulky hydrophobic amino-terminal residues
Phe, Trp, Tyr, and Leu (and Ile in yeast) (5, 7, 11, 13).
Ifa substrate bears both determinants of the N-degron, the
binding of N-recognin is followed by formation of a multi-
ubiquitin chain linked to the N-degron's second determinant,
a specific internal Lys residue (6-9). The coupling of ubiq-
uitin (Ub) to proteins is catalyzed by a family of Ub-
conjugating (UBC) enzymes [also called E2 enzymes (13)]
and involves formation of an isopeptide bond between the
carboxyl-terminal Gly residue of Ub and the E-amino group
of a Lys residue in an acceptor protein (13, 19, 20). In a
multiubiquitin chain, Ub itself serves as an acceptor, with
several Ub moieties attached sequentially to the initial ac-
ceptor protein to form a chain ofbranched Ub-Ub conjugates
(8, 21).
There are seven or more distinct UBC enzymes in S.
cerevisiae; other eukaryotes appear to have at least as many
(20). Two of the yeast UBC enzymes have been identified as
the products of the previously known genes RAD6 (renamed
UBC2) (22), which participates in DNA repair, induced
mutagenesis, sporulation (23-33), and suppression of retro-
transposition (34), and CDC34 (renamed UBC3), which is
required for the transition from G1 to S phase ofthe cell cycle
(35). Two of the other yeast UBC enzymes, UBC4 and
UBC5, have been shown to be required for most of the
Ub-dependent protein degradation in this organism (18, 36).
We now report that UBC2(RAD6) is essential for the
degradation of N-end rule substrates and that UBC2 is
physically associated with the UBRI-encoded N-recognin.
Thus, at least one of the multiple functions of UBC2 is likely
to be mediated by protein degradation via the N-end rule
pathway.
MATERIALS AND METHODS
Plasmids. The plasmid pSOB44 is a derivative of pSOB37
(11), in which the UBRI promoter was replaced with the
- 1.5-kilobase (kb) BamHI fragment from the ADHI promot-
er-containing plasmid pJDcAG1 (37). The plasmid pAD-
HUBC2 was constructed by inserting the -1.5-kb BamHI-
EcoRI fragment from pJDcAG1 into BamHI/EcoRI-cut YE-
placl95 (38). The resultant plasmid was cut with EcoRI, and
the ""0.6-kb EcoRI fragment containing the UBC2 coding
sequence (22) was inserted. pADHUBC2 fully comple-
mented the radiation sensitivity and slow growth phenotypes
of the ubrlA ubc2A BBY68 strain (see the legend to Fig. 4).
Coimmunoprecipitation. Exponential yeast cultures (A6w
< 1) were labeled with [35S]methionine (0.3 mCi/ml; 1 Ci =
37 GBq) for 30 min at 30°C in synthetic medium (11) lacking
methionine. The cells were pelleted by centrifugation, resus-
pended in DB buffer (50 mM NaCI/1 mM Na2EDTA/50 mM
Na Hepes, pH 7.5) containing protease inhibitors leupeptin,
pepstatin A, antipain, chymostatin, and aprotinin (each at 20
Abbreviations: Ub, ubiquitin; UBC, Ub-conjugating; Ub-X-,3gal,
Ub-X-.8-galactosidase.
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FIG. 1. The N-end rule pathway in S. cerevisiae. Primary, secondary, and tertiary destabilizing amino-terminal residues are defined in the
main text; they are denoted by boldface letters using the single-letter abbreviations for amino acids. The shaded ovals indicate the rest of a protein
substrate. Conversion of the tertiary destabilizing residues N and Q into the secondary destabilizing residues D and E (7) is catalyzed by a
deamidase (encoded by DEAI) specific for amino-terminal N and Q (R. Baker and A.V., unpublished data). Conjugation of the primary
destabilizing residue R to the secondary destabilizing amino-terminal residues D and E (7) is catalyzed by the arginyl-tRNA-protein transferase
(R-transferase) encoded by the ATE] gene (10). The distinction between type 1 (R, K, H) and type 2 (L, F, Y, I, W) primary destabilizing
amino-terminal residues is based on their binding to distinct sites on the UBRI-encoded N-recognin (7, 11, 13, 14). If a substrate bears both
determinants of the N-end rule-based degradation signal [the N-degron (2)], the UBR1-associated UBC enzyme encoded by the UBC2 gene (see
main text) uses activated Ub, produced by the UBAI-encoded Ub-activating enzyme (15), to catalyze formation of a substrate-linked
multiubiquitin chain. The latter is required (8) for the substrate's subsequent degradation by an ATP-dependent protease (13, 16, 17).
,&g/ml; Sigma), and lysed by a Vortex treatment with glass
beads (11). The extracts were centrifuged at 12,000 x g for 10
min. Immunoprecipitation assays were carried out with the
supernatants by adding ascitic fluid containing the anti-ha
12CA5 monoclonal antibody (39) to the single or mixed
extracts described in Results. All samples also contained an
'-10-fold excess of an identically prepared unlabeled extract
from untransformed BBY68 cells (see the legend to Fig. 4).
The samples were incubated for 2 hr at 0C; 20 ,1L of protein
A-Sepharose (Repligen) was then added, and the suspensions
were incubated with rocking for 1 hr at 40C, followed by a 3-s
centrifugation in a microcentrifuge. Pellets were washed
three times with 0.5 ml ofDB buffer containing 5% glycerol,
resuspended in electrophoretic sample buffer, heated at
1000C for 3 min, and electrophoresed in a 13% polyacryla-
mide/SDS gel, followed by fluorography.
RESULTS AND DISCUSSION
Ubiquitination and degradation of proteins by the N-end rule
pathway were assayed in vivo using derivatives of Esche-
richia coli p-galactosidase as model substrates. In eukary-
otes, Ub-X-,f-galactosidase (Ub-X-f8gal) fusion proteins are
precisely deubiquitinated by Ub-specific processing prote-
ases to yield X-f3gal test proteins bearing the residue X at the
amino terminus (1, 7). In contrast to the function of Ub in
protein degradation, the role of Ub in these engineered Ub
fusions is simply to allow the generation of X-(3gals bearing
different amino-terminal residues. Depending on the identity
of X, the X-fBgal proteins are either long-lived or metaboli-
cally unstable, with destabilizing amino-terminal residues
conferring short half-lives on the corresponding X-(3gals (1,
6-11).
Which of the yeast UBC enzymes is specific for the N-end
rule pathway? In vivo degradation of the N-end rule sub-
strates (X-Bgals) was tested in ubcl, ubc4, and ubcS null
mutants and found to be either normal or only slightly
reduced in comparison to the congenic wild-type strains (data
not shown). However, these normally short-lived X-f3gals
were found to be dramatically stabilized in a null ubc2(rad6)
mutant.
The X-/3gal test proteins used in these experiments had
either Arg (a type 1 primary destabilizing residue), Leu (a
type 2 primary destabilizing residue), or Met (a stabilizing
residue) at their amino termini. Metabolic stabilities of these
X-fBgals were compared indirectly, by determining their
intracellular levels (Fig. 2), and directly, by pulse-chase
analyses (Fig. 3). Previous work (10, 11, 14) has shown that
the steady-state level of an X-f8gal in yeast cells is a function
of its metabolic stability; compare, for instance, the levels of
Met-fgal [til2 > 20 hr (1)], Arg-pgal [tl/2 2 min (1)], and
Leu-,8gal [ti/2 13 min (1)] expressed from identical vectors in
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FIG. 2. The N-end rule pathway is inactive in a ubc2 null mutant.
Levels of 3gal activity in the wild-type (UBC2) Saccharomyces
cerevisiae strain YPH500 (black bars) and in the congenic ubc2A strain
1BY67 (striped bars) expressing either Ub-Met-fBgal, Ub-Arg-fgal,
Ub-Leu-,8gal, or Ub-Pro-,gal. [Unlike the other 19 Ub-X-,8gals,
Ub-Pro-,Sgal is inefficiently deubiquitinated; its metabolic instability is
independent of the N-degron (see text).] Values shown are the means
of at least four independent measurements. Standard deviations are
shown above each bar. The congenic S. cerevisiae strains YPH500
(MATa ura3-52 lys2-801 ade2-101 trpl-Al his3-A200 leu2O-A) (40) and
BBY67 (a ubc2A:.LEU2 derivative ofYPH500) were transformed with
the previously described (1) 2-Atm-based vectors expressing Ub-X-
,gals from a galactose-inducible promoter. Exponential cultures (A600
< 1) growing at 30°C in SD-galactose medium (1, 6) were assayed for
,-galactosidase activity as described (41).
wild-type (UBC2) cells (Fig. 2, black bars). However, in the
congenic ubc2A cells, which lack the UBC2 Ub-conjugating
enzyme, the levels of Arg-,Bgal and Leu-pgal were greatly
increased and became similar to the level of the long-lived
Met-,Bgal (Fig. 2). Lys-f3gal, His-fgal, Phe-pgal, Tyr-,Bgal,
Ile-pgal, and Trp-/3gal were also tested as described above
and yielded results (data not shown) similar to those with
Arg-(gal and Leu-,Bgal.
These findings were confirmed and extended by pulse-
chase analysis (Fig. 3). Arg-,gal and Leu-f8gal were dramat-
ically stabilized in the ubc2A& background; their half-lives
became indistinguishable from that of the long-lived Met-fgal
(Fig. 3 a and b). As expected from the known enzymatic
activity of UBC2 (22) and the known requirement for mul-
tiubiquitination in the degradation of N-end rule substrates
(7, 8), overexposures of the Fig. 3 fluorograms revealed the
presence of multiubiquitinated Arg-,Bgal and Leu-,Bgal deriv-
atives in the wild-type (UBC2) cells (Fig. 3c) but not in
congenic ubc2A cells (Fig. 3d). We conclude that the UBC2
Ub-conjugating enzyme is essential for the multiubiquitina-
tion and degradation of N-end rule substrates.
The conspicuous and pleiotropic phenotype of ubc2(rad6)
null mutations (22-34) stands in contrast to the relatively mild
phenotype of ubrl null mutations, which also inactivate the
N-end rule pathway (11). Thus, unlike N-recognin, whose
known functions are confined to the N-end rule pathway (11),
the UBC2 enzyme is an essential component not only of this
pathway but at least of one other Ub-dependent pathway as
well. At the same time, the absence of a functional UBC2
enzyme does not inactivate the Ub system in general, as
indicated by the lack of metabolic stabilization of Ub-Pro-
.gal in ubc2A cells (Fig. 3b; compare Fig. 3a). In contrast to
the other 19 Ub-X-Pgals, Ub-Pro-/3gal is inefficiently deu-
biquitinated (1). It is metabolically unstable (1), but its
degradation is independent of the N-degron and N-recognin
(2, 11) and has recently been shown to be mediated by the
amino-terminal Ub moiety of Ub-Pro-(3gal (E. Johnson and
A.V., unpublished data). Remarkably, Ub-Pro-Pgal not only
remained multiubiquitinated and short-lived in the ubc2A
cells (Fig. 3b) but its half-life in fact decreased, from --8 min
in wild-type (UBC2) cells to r2 min in ubc2A cells [Figs. 2
and 3 a and b; half-life values were determined as described
(1, 6)]. Most of the Ub-Pro-Pgal degradation is dependent on
the previously identified (18, 36) UBC4 enzyme (E. Johnson,
B.B., W. Seufert, S. Jentsch, and A.V., unpublished data).
One possibility is that the absence of UBC2 results in
overexpression of either the UBC4 enzyme or a UBC4-
associated recognin.
The UBC2-mediated multiubiquitination of an N-end rule
substrate requires, and is preceded by, substrate binding by
the UBRI-encoded N-recognin. This functional proximity of
UBR1 and UBC2 is underscored by their physical associa-
tion, which was demonstrated by coimmunoprecipitation
(Fig. 4). In this experiment, a modified UBR1 protein was
used, whose carboxyl terminus was extended with a nine-
residue epitope (derived from hemagglutinin (ha) of influenza
virus) that is recognized by a monoclonal antibody (39). The
epitope-tagged UBR1 (UBRi-ha) was functionally active, in
that the UBRl-ha gene complemented the ubrlA mutant to
the same extent as the unmodified UBRJ gene (11). When
overexpressed from the ADHI promoter on a high copy
plasmid, the '226-kDa UBRl-ha protein could be immuno-
precipitated with the anti-ha monoclonal antibody from
[35Slmethionine-labeled cell extracts (ref. 11 and Fig. 4, lane
c). Extracts were prepared from (35S~methionine-labeled
ubrlA ubc2A cells transformed with either a control plasmid
(vector alone), a plasmid expressing UBRi-ha, or a plasmid
expressing UBC2. The control extract (lacking UBRi-ha and
UBC2) was processed for immunoprecipitation with the
anti-ha monoclonal antibody either alone (Fig. 4, lane a) or
after having been mixed with either the UBC2-containing
extract (Fig. 4, lane b) or the extract containing UBRi-ha
(Fig. 4, lane c). The UBC2-containing extract was also mixed
with the extract containing UBRi-ha, and the mixed extract
was immunoprecipitated with the anti-ha antibody (Fig. 4,
lane d). This antibody precipitated the UBR1-ha protein from
samples containing UBR1-ha (Fig. 4, lanes c and d) and did
not precipitate a protein the size of UBC2 (19.7 kDa) from
samples containing UBC2 but lacking 1UBR1-ha (Fig. 4, lane
b). However, the immunopredipitation from the sample con-
taining both UBRI-ha and UBC2 yielded not only UBR1-ha
but also a protein the size of UBC2 (Fig. 4, lane d; compare
lane c). We conclude that the UBC2 Ub-conjugating enzyme
is physically associated with the UBRI-encoded N-recognin.
In agreement with this result, Reiss et al. (42) have observed,
using sedimentation assays, that the partially purified N-rec-
ognin (type 1, 2 E3 protein) from rabbit reticulocytes binds to
one or more of the UBC enzymes present in reticulocyte
extract.
In addition to identifying one specific function ofthe UBC2
enzyme, the discovery of its role in the N-end rule pathway
opens new directions for studies of this pathway. For exam-
ple, an -100-fold increase in the frequency of transposition
of the S. cerevisiae Tyl retrotransposon in ubc2 mutants (34)
is consistent with the possibility that the N-end rule pathway
is involved in the regulation of retrotransposition. Further-
more, the analysis of targeting and ubiquitination in the
N-end rule pathway can now be aided by developing an in
Biochemistry: Dohmen et al.
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FiG. 3. Pulse-chase analysis of X-pgal degradation in UBC2 and ubc2A cells. (a) Exponential cultures of the wild-type (UBC2) S. cerevisiae
strain YPH500 (see legend to Fig. 2) expressing either Ub-Met-pal, Ub-Arg-Mal, Ub-Leu-*al, or Ub-Pro-pgal were labeled with [35S]methionine
for 5 min at 30WC (lanes 0'), followed by a chase in the presence of unlabeled methionine and the translation inhibitors cycloheximide and
trichodermin for 10 and 30 min (lanes 10' and 30', respectively), extraction, immunoprecipitation, and electrophoretic analysis of X-gal as
described (11). The bands ofX-figals and of(inefficiently deubiquitinated) Ub-Pro-Wgalare indicated. An arrowhead denotes an '90-kDa long-lived
gal cleavage product specific for short-lived X-gals and Ub-Pro-fgal (1, 11). Half-open square brackets indicate the bands of multiply
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vitro system that contains defined (cloned) components,
including the UBC2 gene product. Other relevant yeast
genes, such as UBAI [encoding Ub-activating enzyme (15)],
UBRI [encoding N-recognin (11)], and UBPI-UBP3 [encod-
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ing Ub-specific processing proteases (J. Tobias, R. Baker,
and A.V., unpublished data)], have recently become avail-
able as well.
Genetic and biochemical approaches will now make possi-
ble precise distinctions between those functions of the UBC2
enzyme that are dependent on its interaction with N-recognin
(11) (Fig. 4) and those mediated by other, still unknown
UBC2-binding recognins specific for signals other than the
N-degron. These distinctions will encompass growing and
sporulating yeast cells; while both UBRI and UBC2 are
expressed during sporulation (ref. 33 and data not shown), the
absence of the N-end rule pathway (in ubri mutants) results in
a mild sporulation defect (increased content oftwo-spore asci)
(11), whereas the absence of both the N-end rule and other
UBC2-dependent pathways (in ubc2 mutants) either precludes
(25, 26) or severely perturbs (31) sporulation.
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FIG. 4. UBC2 binds to UBRL. Extracts were prepared from
[35S]methionine-labeled BBY68 cells [ubrlA ubc2&:.:LEU2, a haploid
derivative of YPH5O1 (40)] transformed with either the control high
copy plasmid YEplac1l2 (ref. 38; a vector alone), the plasmid
pSOB44 (expressing the epitope-tagged UBR1-ha from the ADHI
promoter), or the plasmid pADHUBC2 (expressing UBC2 from the
ADHI promoter). The extract containing UBC2 (7.5 x 104 acid-
insoluble cpm) was mixed with either the control extract (1.5 x 105
cpm) lacking UBC2 and UBR1-ha (lane b) or the extract containing
UBR1-ha (1.5 x 105 cpm) (lane d). The extract containing UBR1-ha
(1.5 x 10i cpm) was also mixed with the control extract (7.5 x 104
cpm) (lane c). These three samples and the control extract alone (2.25
x 105 cpm) (lane a) were immunoprecipitated with a monoclonal
antibody to the ha epitope (39), followed by SDS/PAGE and
fluorography. The bands ofUBR1-ha and UBC2 are indicated. Bands
present in all four lanes (major species marked by dots) correspond
to proteins that cross-react with the anti-ha monoclonal antibody.
Molecular masses (in kDa) of prestained markers (Diversified Bio-
tech) are shown on the left.
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Counterparts of the yeast UBRI-encoded N recogriin (11)
and UBC2 Ub-conjugating enzyme (22) exist in mammals (5,
7, 13, 43, 44). Thus, a functional and mechanistic dissection
of the yeast UBR1/UBC2 complex identified in the present
work should also advance the understanding of the N-end
rule pathway in higher organisms.
We thank Daniel Gietz for the plasmids YEplacll2 and YEplacl95
and Barbara Doran for secretarial assistance. This research was
supported by grants to A.V. from the National Institutes of Health
(DK39520 and GM31530). R.J.D. and K.M. were supported by
fellowships from the European Molecular Biology Organization and
the American Cancer Society, respectively.
1. Bachmair, A., Finley, D. & Varshavsky, A. (1986) Science 234,
179-186.
2. Varshavsky, A. (1991) Cell 64, 13-15.
3. Varshavsky, A., Bachmair, A., Finley, D., Gonda, D. &
Wunning, I. (1988) in Ubiquitin, ed. Rechsteiner, M. (Plenum,
New York), pp. 287-324.
4. Townsend, A., Bastin, J., Gould, K., Brownlee, G., Andrew,
M., Coupar, B., Boyle, D., Chang, S. & Smith, G. (1988) J.
Exp. Med. 168, 1211-1224.
5. Reiss, Y., Kaim, D. & Hershko, A. (1988) J. Biol. Chem. 263,
2693-2698.
6. Bachmair, A. & Varshavsky, A. (1989) Cell 56, 1019-1032.
7. Gonda, D. K., Bachmair, A., Wunning, I., Tobias, J. W.,
Lanes, W. S. & Varshavsky, A. (1989) J. Biol. Chem. 264,
16700-16712.
8. Chau, V., Tobias, J. W., Bachmair, A., Marriott, D., Ecker,
D. J., Gonda, D. K. & Varshavsky, A. (1989) Science 243,
1576-1583.
9. Johnson, E. S., Gonda, D. K. & Varshavsky, A. (1990) Nature
(London) 346, 287-291.
10. Balzi, E., Choder, M., Chen, W., Varshavsky, A. & Goffeau,
A. (1990) J. Biol. Chem. 265, 7464-7471.
11. Bartel, B., Wunning, I. & Varshavsky, A. (1990) EMBO J. 9,
3179-3189.
12. Elias, S. & Ciechanover, A. (1990) J. Biol. Chem. 265, 15511-
15517.
13. Hershko, A. (1988) J. Biol. Chem. 263, 15237-15240.
14. Baker, R. T. & Varshavsky, A. (1991) Proc. NatI. Acad. Sci.
USA 88, 1090-1094.
15. McGrath, J. P., Jentsch, S. & Varshavsky, A. (1991) EMBO J.
10, 227-236.
16. Ciechanover, A. & Schwartz, A. L. (1989) Trends Biochem.
Sci. 14, 483-488.
17. Driscoll, J. & Goldberg, A. L. (1990) J. Biol. Chem. 265,
4789-4792.
18. Reiss, Y. & Hershko, A. (1990) J. Biol. Chem. 265, 3685-3690.19. Pickart, C. M. & Rose, I. A. (1985) J. Biol. Chem. 260,
1573-1581.
20. Jentsch, S., Seufert, W., Sommer, T. & Reins, H.-A. (1990)
Trends Biochem. Sci. 15, 195-198.
21. Gregori, L., Poosch, M. S., Cousins, G. & Chau, V. (1990) J.
Biol. Chem. 265, 8354-8357.
22. Jentsch, S., McGrath, J. P. & Varshavsky, A. (1987) Nature(London) 329, 131-134.
23. Cox, B. S. & Parry, J. M. (1968) Mutat. Res. 6, 37-55.
24. Lawrence, C. W., Stewart, J. W., Sherman, F. & Christensen,
R. (1974) J. Mol. Biol. 85, 137-162.
25. Game, J. C., Zamb, T. J., Braun, R. J., Resnik, M. & Roth,
R. M. (1980) Genetics 94, 51-68.
26. Montelone, B. A., Prakash, S. & Prakash, L. (1981) Mol. Gen.
Genet. 184, 410-415.
27. Kupiec, M. & Simchen, G. (1984) Curr. Genet. 8, 559-866.
28. Borts, R. H., Lichten, M. & Haber, J. E. (1986) Genetics 113,
551-567.
29. Reynolds, P., Weber, S. C. & Prakash, L. (1985) Proc. Natl.
Acad. Sci. USA 82, 168-172.
30. Friedberg, E. C. (1988) Microbiol. Rev. 52, 70-102.
31. Morrison, A., Miller, E. J. & Prakash, L. (1988) Mol. Cell. Biol.
8, 1179-1185.
32. Sung, P., Prakash, S. & Prakash, L. (1988) Genes Dev. 2,
1476-1485.
33. Madura, K., Prakash, S. & Prakash, L. (1990) Nucleic Acids
Res. 18, 771-778.
34. Picologlou, S., Brown, N. & Liebman, S. (1990) Mol. Cell. Biol.
10, 1017-1022.
35. Goebl, M., Yochem, J., Jentsch, S., McGrath, J. P., Var-
shavsky, A. & Byers, B. (1988) Science 241, 1331-1335.
36. Seufert, W. & Jentsch, S. (1990) EMBO J. 9, 543-550.
37. Dohmen, R. J., Strasser, A. W. M., Dahlems, U. M. & Hol-
lenberg, C. P. (1990) Gene 95, 111-121.
38. Gietz, R. D. & Sugino, A. (1988) Gene 74, 527-534.
39. Field, J., Nikawa, J. I., Broek, D., MacDonald, B., Rodgers,
L., Wilson, I. A., Lerner, R. A. & Wigler, M. (1988) Mol. Cell.
Biol. 8, 2159-2165.
40. Sikorski, R. S. & Hieter, P. (1989) Genetics 122, 19-27.
41. Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D.,
Seidman, J. G., Smith, J. A. & Struhl, K. (1987) Current
Protocols in Molecular Biology (Wiley/Interscience, New
York).
42. Reiss, Y., Heller, H. & Hershko, A. (1989) J. Biol. Chem. 264,
10378-10383.
43. Schneider, R., Eckerskom, C., Lottspeich, F. & Schweiger, M.(1990) EMBO J. 9, 1431-1435.
44. Berleth, E. S. & Pickart, C. M. (1990) Biochem. Biophys. Res.
Commun. 171, 705-710.
Biochemistry: Dohmen et aL
